Background: Vinorelbine and Doxil (liposomal doxorubicin) are active chemotherapeutic agents in metastatic breast cancer. A phase I study was designed to evaluate combination therapy.
Doxorubicin-containing regimens remain important in treating metastatic breast cancer, with response rates between 40% and 60%. The principal dose-limiting toxicity is myelosuppression, and in cumulative doses, cardiac toxicity, while alopecia and nausea/vomiting are common side effects. Vinorelbine (Navelbine, Glaxo Wellcome, Research Triangle Park, NC) is a semisynthetic vinca alkaloid with principal toxicities being myelosuppression and neurotoxicity [1] . As first line therapy for metastatic breast cancer, vinorelbine has response rates of 35%-45% [2, 3] , and retains response rates of 16%-35% as a second line agent among patients with prior anthracycline or paclitaxel exposure [3] [4] [5] . Combination therapy with doxorubicin and vinorelbine has been associated with response rates of 35%-82%, and is thought to be well tolerated, with neutropenia being the dose-limiting toxicity [6] . Doxil (Sequus Pharmaceuticals, Menlo Park, CA) is a formulation of doxorubicin encapsulated in small, sterically stabilized, liposomal vesicles. Doxil has a longer half-life than doxorubicin and different tissue distribution, with preferential concentration in tumors [7] . In clinical trials, liposomal doxorubicin causes less cardiac toxicity, neutropenia, and alopecia than free doxorubicin [8, 9] . However, Doxil has been associated with stomatitis and palmar-plantar erythrodysesthesia (PPE; hand-foot syndrome), which are dose limiting after repetitive treatments. In a multicenter trial using Doxil as single agent therapy for metastatic breast cancer, 31% of patients had objective responses [10] . A phase I trial of vinorelbine with Doxil was conducted to determine a safe dose and treatment schedule for administration of these agents in women with metastatic breast cancer.
Patients and methods

Eligibility
The study was conducted at Duke University Medical Center and Dana-Farber Cancer Institute, with approval of both institutional review boards. Informed consent was required for patient participation. Patients with metastatic breast cancer who had received 0-3 prior chemotherapy regimens cancer were eligible. Prior doxorubicin treatment ($360 mg/m 2 cumulative dose) was allowed provided that left ventricular ejection fraction remained > 5 0 % on MUGA scan. Other eligibility requirements included: Eastern Cooperative Oncology Group performance status $ 2 . absolute neutrophil count (ANC) 5 1500/ul. platelet count (PLT) > 100,000/ul, hemoglobin ^ 9 mg/dl, creatinine < 2 x upper limit of normal, bilirubin < 1.5 x upper limit of normal, SGOT < 2 x upper limit of normal.
Treatment plan
All patients who received at least one dose of Doxil and/or vinorelbine were included for analysis. Patients were treated on 28-day cycles. Doxil was administered by i.v. infusion over one hour on day 1 only Five minutes after the Doxil infusion, vinorelbine was administered by i.v. injection over 6 to 10 minutes and followed by flushing with at least 75-125 ml of i.v. solution. Standard anti-emetic medications, generally dexamethasone. were given. Patients who developed acute but mild infusion reactions to Doxil continued to receive the infusion at onehalf the infusion rate. For persistent symptoms or severe reactions, treatment was stopped. If symptoms resolved immediately upon discontinuation, the infusion was restarted at one-half the prior rate. A MUGA scan was performed once total doxorubicin dose (free plus liposomal) reached 400 mg/m 2 , and every two cycles of therapy thereafter. Dose-intensity was determined by dividing total dose received by the number of weeks on protocol.
Toxicity criteria and assessment Dose-limiting toxicity (DLT) was defined during the first-cycle of treatment as: any grade 3 or 4 non-hematological toxicity; ANC < 500 for > 7 days; febrile neutropenia; PLT < 25.000; any persistent grade 2 non-hematological toxicity that prevented retreatment at full doses for more than two weeks. Maximally tolerated dose (MTD) was determined through dose escalation, and was the treatment level below that in which DLT was observed in at least two of three patients. Once MTD was determined, a total of eight patients were enrolled in that cohort to ensure safety and confirm the appropriateness of MTD for phase II dose recommendations. Toxicities were graded using standard NCI toxicity scales.
After the first cycle, Doxil and vinorelbine doses and schedules were adjusted for predefined toxicity. A 25% dose reduction of both Doxil and vinorelbine was made for grade 4 neutropenia or thrombocytopenia. Treatment was delayed for up to two weeks for ANC < 1500 or PLT < 100,000 on planned treatment days. Treatment was also delayed for up to two weeks for grade ^ 2 mucositis or neurologic toxicity. If mucositis improved but did not fully resolve, repeat dosing was allowed with a 25% dose reduction of Doxil. Similarly, repeat dosing with a 25% dose reduction in vinorelbine was allowed for persistent grade 2 neurologic toxicity. Chemotherapy was delayed one week for PPE of grade 3 or 4 that resolved to grade 1 or 2 on the planned day of treatment. If grade I or 2 toxicity persisted two weeks, the Doxil dose was reduced by 25%. Patients requiring greater than two weeks treatment delay for any reason were taken off study, as were patients with bilirubin > 3.0 mg/dl.Vinorelbine administration on day 8/15 was held for ANC < 500. Other grade 3 or 4 toxicities not discussed above were managed with a 25% dose reduction in Doxil.
Pharmacokinetic analysis
Pharmacokinetic studies were performed on plasma samples taken during cycle 1. only. Specimens were obtained prior to the Doxil infusion, and at the following time points from ending the first vinorelbine infusion: 5 min, 20 min, 45 min, 1.5 hours, 2.5 hours, 4.5 hours, 8 hours. 24 hours, 48 hours, 72 hours and 96 hours. Plasma doxorubicin concentrations were quantified following solid-phase extraction by modification of a technique using reverse-phase HPLC with fluorescence detection [11] .
Results
Dose escalation and determination of MTD
Thirty women (mean age 54) were enrolled: most had performance status 0 or 1, and at least two sites of metastatic disease. Seventy-six percent had received prior chemotherapy and sixty-three percent had received prior doxorubicin. Patients in cohort I were treated with Doxil 30 mg/m 2 on day 1 and vinorelbine 25 mg/m 2 on days 1 and 8 ( Table 1) . Three of four patients developed dose-limiting toxicity related to neutropenia. Because of hematologic toxicity, the vinorelbine schedule was changed to days 1 and 15, and dose escalation resumed. Dose-limiting toxicity was again observed in cohort III (Table 1) . As the dose for cohort II appeared to be the MTD, additional patients were enrolled at this dose level. When none of these patients experienced DLT, it was decided to proceed with another cohort, IIA (Table 1) . Eight patients were treated without developing DLT, establishing this cohort as the MTD.
Treatment outcomes
Patients were observed throughout the study for toxicity. The highest grade of toxicity for any cycle of treatment is shown in the table, along with the required dose modifications and calculated dose intensity. Neutropenia was common, while gastrointestinal side effects and alopecia were mild. For patients experiencing ANC < 500, median time to neutrophil recovery was five days. PPE was observed after repetitive dosing, though was generally mild and in most instances treatment proceeded through PPE with an occasional treatment delay.
One patient who had been previously treated with doxorubicin was taken off protocol for grade 2 cardiac toxicity, after an asymptomatic decline in ejection fraction from 62% to 46% following six cycles on protocol (cumulative doxorubicin dose 597 mg/m 2 ). Clinical responses were observed across treatment cohorts. Of the 24 patients with evaluable disease, 6 patients had partial responses to therapy, and several other patients had disease stabilization (> 6 months) often associated with improvements in tumor markers.
P/iarmacokinetics
Plasma Doxil concentrations (measured as doxorubicin equivalents) were analyzed in 12 patients and found to be persistently elevated and detectable throughout the sampling period of 96 hours, as depicted in Figure 1 . No patients had detectable plasma concentrations of the doxorubicin metabolite, doxorubicinol. Traditional compartmental pharmacokinetic models could not consistently describe a majority of patients' disposition curves due to erratic fluctuations in concentrations during the initial nine hours of sampling (data not shown).
Discussion
This study sought to define a well tolerated treatment regimen incorporating both Doxil and vinorelbine. The recommended phase II doses are: Doxil 40 mg/m 2 day 1, and vinorelbine 30 mg/m 2 days 1 and 15, given on a 28-day cycle, and a phase II study is underway to assess the efficacy of this combination. Limiting toxicities were myelosuppression and mucositis, while fatigue, GI distress, and PPE were mild and quite manageable. Dose intensity achieved in combination therapy at the recommended levels was comparable to dose intensity observed when using Doxil or vinorelbine as single agent therapy.
Vinorelbine has been administered on days 1 and 8 of the treatment cycle when used in combination with free doxorubicin. Substitution of free doxorubicin with liposomal doxorubicin required delaying the second vinorelbine dose until day 15 because of neutropenia. The persistence of high doxorubicin concentrations for several days following treatment with liposomal doxorubicin may account for this clinical observation. Similar pharmacokinetic patterns have been observed in other clinical trials of Doxil [12] .
Doxil-doxorubicin and vinorelbine are potentially active against a variety of other tumor types, including lung cancer, ovarian cancer, and sarcoma. Doxilvinorelbine merits investigation in these patient populations.
